These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 35081849)

  • 1. Biological agents targeting interleukin-13 for atopic dermatitis.
    Chiricozzi A; Gori N; Maurelli M; Gisondi P; Caldarola G; De Simone C; Peris K; Girolomoni G
    Expert Opin Biol Ther; 2022 May; 22(5):651-659. PubMed ID: 35081849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic targeting of the IL-13 pathway in skin inflammation.
    Tubau C; Puig L
    Expert Rev Clin Immunol; 2021 Jan; 17(1):15-25. PubMed ID: 33275064
    [No Abstract]   [Full Text] [Related]  

  • 3. Selective IL-13 inhibitors for the treatment of atopic dermatitis.
    Gonçalves F; Freitas E; Torres T
    Drugs Context; 2021; 10():. PubMed ID: 33889195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of IL-13: A New Pathway for Atopic Dermatitis [Formula: see text].
    Ratnarajah K; Le M; Muntyanu A; Mathieu S; Nigen S; Litvinov IV; Jack CS; Netchiporouk E
    J Cutan Med Surg; 2021; 25(3):315-328. PubMed ID: 33350863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Targeted Biological Agents for the Treatment of Atopic Dermatitis.
    Yang N; Chen Z; Zhang X; Shi Y
    BioDrugs; 2021 Jul; 35(4):401-415. PubMed ID: 34213742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of IL-13 inhibitors in atopic dermatitis: A systematic review and meta-analysis.
    Zhang Y; Jing D; Cheng J; Chen X; Shen M; Liu H
    Front Immunol; 2022; 13():923362. PubMed ID: 35967348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-13 antagonists in the treatment of atopic dermatitis.
    Tubau C; Puig L
    Immunotherapy; 2021 Mar; 13(4):327-344. PubMed ID: 33430628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial.
    Guttman-Yassky E; Blauvelt A; Eichenfield LF; Paller AS; Armstrong AW; Drew J; Gopalan R; Simpson EL
    JAMA Dermatol; 2020 Apr; 156(4):411-420. PubMed ID: 32101256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches.
    Moyle M; Cevikbas F; Harden JL; Guttman-Yassky E
    Exp Dermatol; 2019 Jul; 28(7):756-768. PubMed ID: 30825336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tralokinumab for the Treatment of Atopic Dermatitis.
    Freitas E; Guttman-Yassky E; Torres T
    Am J Clin Dermatol; 2021 Sep; 22(5):625-638. PubMed ID: 34155602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb.
    Wollenberg A; Howell MD; Guttman-Yassky E; Silverberg JI; Kell C; Ranade K; Moate R; van der Merwe R
    J Allergy Clin Immunol; 2019 Jan; 143(1):135-141. PubMed ID: 29906525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Innovation in Atopic Dermatitis: From Pathogenesis to Treatment.
    Munera-Campos M; Carrascosa JM
    Actas Dermosifiliogr (Engl Ed); 2020 Apr; 111(3):205-221. PubMed ID: 31964499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologics for Atopic Dermatitis.
    Boguniewicz M
    Immunol Allergy Clin North Am; 2020 Nov; 40(4):593-607. PubMed ID: 33012322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Interleukin 13 for the Treatment of Atopic Dermatitis.
    Lytvyn Y; Gooderham M
    Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE).
    Simpson EL; Flohr C; Eichenfield LF; Bieber T; Sofen H; Taïeb A; Owen R; Putnam W; Castro M; DeBusk K; Lin CY; Voulgari A; Yen K; Omachi TA
    J Am Acad Dermatol; 2018 May; 78(5):863-871.e11. PubMed ID: 29353026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Commonality of the IL-4/IL-13 pathway in atopic diseases.
    Gandhi NA; Pirozzi G; Graham NMH
    Expert Rev Clin Immunol; 2017 May; 13(5):425-437. PubMed ID: 28277826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The IL-4, IL-13 and IL-31 pathways in atopic dermatitis.
    Dubin C; Del Duca E; Guttman-Yassky E
    Expert Rev Clin Immunol; 2021 Aug; 17(8):835-852. PubMed ID: 34106037
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy of biologics in atopic dermatitis.
    Wu J; Guttman-Yassky E
    Expert Opin Biol Ther; 2020 May; 20(5):525-538. PubMed ID: 32003247
    [No Abstract]   [Full Text] [Related]  

  • 19. New and Emerging Systemic Treatments for Atopic Dermatitis.
    Newsom M; Bashyam AM; Balogh EA; Feldman SR; Strowd LC
    Drugs; 2020 Jul; 80(11):1041-1052. PubMed ID: 32519223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asthma and Atopic Dermatitis: A Review of Targeted Inhibition of Interleukin-4 and Interleukin-13 As Therapy for Atopic Disease.
    Buzney CD; Gottlieb AB; Rosmarin D
    J Drugs Dermatol; 2016 Feb; 15(2):165-71. PubMed ID: 26885783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.